Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Program Official
Principal Investigator
Anthony J Jaslowski
Awardee Organization

St. Vincent Hospital
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Cancer Research of Wisconsin and Northern Michigan (CROWN) Consortium

The Cancer Research of Wisconsin and Northern Michigan (CROWN) Consortium is a collaboration among three major cancer care systems in Wisconsin: St. Vincent Hospital Cancer Centers (SVHCC), Wheaton Franciscan Healthcare - Southeast Wisconsin, Inc., Ministry Healthcare, Inc., and Columbia St. Mary’s, Inc. (collectively, Ascension Wisconsin), and Aspirus, Inc. SVHCC serves as the primary performance site. Together, these institutions and their affiliates provide access to National Cancer Institute (NCI)-sponsored clinical trials across a wide geographic region that includes both urban and rural areas in Wisconsin and northern Michigan. The CROWN Consortium aims to broaden participation in clinical trials through expanded recruitment infrastructure, shared operational resources, and regular coordination via established consortium committees. The consortium supports implementation of Cancer Care Delivery Research (CCDR) across multiple sites and actively contributes to NCORP Research Base activities, including committee service, protocol input, and mentoring of early-career investigators. The CROWN Consortium brings a robust research infrastructure and multidisciplinary expertise across medical and radiation oncology, pediatric oncology, and palliative care. It offers a comprehensive portfolio of clinical trials to the community setting, including studies in cancer prevention, control, care delivery, imaging, treatment, and biospecimen collection. These efforts serve to increase trial access and generate broadly applicable research findings from a range of practice settings. The specific aims of the CROWN Consortium include 1) broadening consortium participation in NCI-sponsored clinical trials by expanding recruitment, clinical capabilities, and resource sharing; 2) execution of high-quality Cancer Care Delivery Research (CCDR) across the consortium; and 3) increasing investigator engagement in NCORP initiatives by contributing to best practices and research findings. The CROWN Consortium strengthens the NCORP network by expanding access to clinical trials through the implementation and evaluation of trials across the community oncology landscape.

Publications

  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 10;39(23):2539-2551. Epub 2021 Jun 6. PMID: 34092112
  • Smith KL, Zhao F, Mayer IA, Tevaarwerk AJ, Garcia SF, Arteaga CL, Symmans WF, Park BH, Burnette BL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Brown-Glaberman U, Flaum LE, Mayer EL, Sikov WM, Rodler ET, DeMichele AM, Sparano JA, Wolff AC, Miller KD, Wagner LI. Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131. Cancer. 2024 May 15;130(10):1747-1757. Epub 2024 Jan 18. PMID: 38236702
  • Mayer IA, Zhao F, Arteaga CL, Symmans WF, Park BH, Burnette BL, Tevaarwerk AJ, Garcia SF, Smith KL, Makower DF, Block M, Morley KA, Jani CR, Mescher C, Dewani SJ, Tawfik B, Flaum LE, Mayer EL, Sikov WM, Rodler ET, Wagner LI, DeMichele AM, Sparano JA, Wolff AC, Miller KD. Reply to T. Shimoi et al and Y. Shimanuki et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Nov 1;39(31):3522-3524. Epub 2021 Sep 23. PMID: 34554848